Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 21 November, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo
Stock Ticker - BSE: 506820 | NSE: ASTRAZEN

Astrazeneca Pharma India Ltd: Intrinsic Value and Fundamental Analysis

Share Price and Basic Stock Data

Last Updated: November 21, 2024, 10:27 pm

Market Cap 15,762 Cr.
Current Price 6,305
High / Low8,140/4,050
Stock P/E122
Book Value 272
Dividend Yield0.38 %
ROCE31.1 %
ROE22.9 %
Face Value 2.00
PEG Ratio8.69

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Astrazeneca Pharma India Ltd

Competitors of Astrazeneca Pharma India Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Gujarat Themis Biosyn Ltd 3,465 Cr. 318390/10865.7 20.50.21 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 59.8 Cr. 80.694.9/25.822.9 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 28.0 Cr. 19.119.5/8.3536.3 6.640.00 %4.06 %3.33 % 10.0
Godavari Drugs Ltd 85.5 Cr. 114155/87.012.8 55.40.00 %12.7 %15.5 % 10.0
Glenmark Life Sciences Ltd 13,221 Cr. 1,0801,335/62031.2 2072.08 %28.1 %21.1 % 2.00
Industry Average19,460.76 Cr1,177.0554.20184.880.33%16.40%16.92%6.61

All Competitor Stocks of Astrazeneca Pharma India Ltd

Quarterly Result

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales200210175198201232232236250285295311306
Expenses170170160180186194204195213225228258291
Operating Profit31401618153828413760675315
OPM %15%19%9%9%7%16%12%17%15%21%23%17%5%
Other Income333354477-3282510
Interest0000000000001
Depreciation5654445344444
Profit before tax28371416163727443923717320
Tax %26%26%24%26%30%24%26%26%26%26%25%29%22%
Net Profit21271012112820332917545216
EPS in Rs8.4210.914.104.784.5711.198.0613.0211.726.9121.5420.956.32

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales5313904745175645445717288328148061,0031,197
Expenses5014594875285475065256577116787198381,002
Operating Profit30-68-13-111637467112113586165195
OPM %6%-18%-3%-2%3%7%8%10%15%17%11%16%16%
Other Income6102367141216131315-1410
Interest0000000011111
Depreciation7121015171615151920171615
Profit before tax29-700-21636447311412783134188
Tax %32%-27%0%9%44%41%25%37%27%26%26%
Net Profit20-90-1-21520265472936299139
EPS in Rs7.90-35.81-0.20-8.342.108.0210.3621.7828.8837.3224.6439.7255.72
Dividend Payout %44%0%0%0%0%0%0%0%3%5%41%40%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2012-20132013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-2023
YoY Net Profit Growth (%)-550.00%98.89%-2000.00%123.81%300.00%30.00%107.69%33.33%29.17%-33.33%59.68%
Change in YoY Net Profit Growth (%)0.00%648.89%-2098.89%2123.81%176.19%-270.00%77.69%-74.36%-4.17%-62.50%93.01%

Astrazeneca Pharma India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2012-2013 to 2022-2023.

Growth

Compounded Sales Growth
10 Years:11%
5 Years:12%
3 Years:17%
TTM:30%
Compounded Profit Growth
10 Years:27%
5 Years:22%
3 Years:18%
TTM:-26%
Stock Price CAGR
10 Years:22%
5 Years:19%
3 Years:28%
1 Year:35%
Return on Equity
10 Years:17%
5 Years:21%
3 Years:20%
Last Year:23%

Last Updated: Unknown

Balance Sheet

Last Updated: November 15, 2024, 1:40 am

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital5555555555555
Reserves95167146151218242296359451506584707674
Borrowings0000000121297517
Other Liabilities206244261247193214261330306337389362545
Total Liabilities3064164124034154615627067758579851,0781,241
Fixed Assets259410197877575728174696769
CWIP7491265472442100
Investments0000000000000
Other Assets2083122982993243824806116907809151,0111,172
Total Assets3064164124034154615627067758579851,0781,241

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +-6-1-465738955871051015828
Cash from Investing Activity +-16-15-19-40-94-17117351822
Cash from Financing Activity +-10860-1000-6-9-9-24-44
Net Cash Flow-3271-645338-159-9026996525

Free Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Free Cash Flow30.00-68.00-13.00-11.0016.0037.0046.0071.00109.00123.0077.00158.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days264130542935403738393943
Inventory Days202210157141121229186197198164193140
Days Payable214241203174184257266251221223231121
Cash Conversion Cycle1410-1621-347-39-1715-20162
Working Capital Days-56-45-15-28-36-8-14-15-15-33-1720
ROCE %-53%-12%-13%4%15%19%27%34%30%16%31%31%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
Promoters75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%
FIIs2.38%2.38%2.48%2.49%2.61%2.70%2.68%2.69%2.66%2.73%2.79%2.90%
DIIs1.14%1.19%1.30%1.32%1.42%1.41%1.91%2.42%2.76%3.77%4.99%5.08%
Public21.48%21.43%21.22%21.19%20.97%20.88%20.40%19.89%19.57%18.50%17.21%17.02%
No. of Shareholders62,18357,76053,98049,08545,61942,14638,94632,38029,03229,41827,16927,615

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Nippon India Small Cap Fund645,8500.93427.33722024-11-20896913.89%
Nippon India Pharma Fund11,5610.117.65722024-11-2015956.94%
ICICI Prudential MNC Fund5,6670.243.75722024-11-207770.83%
ICICI Prudential S&P BSE 500 ETF720.030.05722024-11-200%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue2.002.002.002.002.00
Basic EPS (Rs.)64.6039.7024.6037.3028.90
Diluted EPS (Rs.)64.6039.7024.6037.3028.90
Cash EPS (Rs.)70.5846.2231.4245.3736.32
Book Value[Excl.RevalReserv]/Share (Rs.)284.77235.48204.56182.47145.78
Book Value[Incl.RevalReserv]/Share (Rs.)284.77235.48204.56182.47145.78
Dividend / Share (Rs.)24.0016.0010.002.001.00
Revenue From Operations / Share (Rs.)518.21401.19322.24325.42332.72
PBDIT / Share (Rs.)87.7076.4940.3859.3253.48
PBIT / Share (Rs.)81.7269.9833.6051.2746.04
PBT / Share (Rs.)87.8153.6433.2250.8445.59
Net Profit / Share (Rs.)64.6039.7224.6437.3228.88
PBDIT Margin (%)16.9219.0612.5218.2216.07
PBIT Margin (%)15.7717.4410.4215.7513.83
PBT Margin (%)16.9413.3710.3015.6213.70
Net Profit Margin (%)12.469.897.6411.468.68
Return on Networth / Equity (%)22.6816.8612.0420.4519.81
Return on Capital Employeed (%)28.3429.1116.0327.2030.36
Return On Assets (%)14.9810.087.1912.0410.22
Asset Turnover Ratio (%)1.261.090.981.101.31
Current Ratio (X)2.612.182.122.041.66
Quick Ratio (X)1.971.681.701.511.15
Inventory Turnover Ratio (X)0.610.510.590.590.49
Dividend Payout Ratio (NP) (%)0.0020.148.115.353.46
Dividend Payout Ratio (CP) (%)0.0017.306.364.402.75
Earning Retention Ratio (%)0.0079.8691.8994.6596.54
Cash Earning Retention Ratio (%)0.0082.7093.6495.6097.25
Interest Coverage Ratio (X)182.60303.52106.25136.06117.27
Interest Coverage Ratio (Post Tax) (X)121.83222.4665.8486.6064.34
Enterprise Value (Cr.)12795.167617.775940.177173.155726.36
EV / Net Operating Revenue (X)9.887.607.378.826.88
EV / EBITDA (X)58.3639.8458.8548.3742.83
MarketCap / Net Operating Revenue (X)10.278.097.939.257.19
Retention Ratios (%)0.0079.8591.8894.6496.53
Price / BV (X)18.6813.7912.4916.5016.41
Price / Net Operating Revenue (X)10.278.097.939.257.19
EarningsYield0.010.010.010.010.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Astrazeneca Pharma India Ltd as of November 21, 2024 is: 7,628.01

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 21, 2024, Astrazeneca Pharma India Ltd is Undervalued by 20.98% compared to the current share price 6,305.00

Intrinsic Value of Astrazeneca Pharma India Ltd as of November 21, 2024 is: 8,699.49

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 21, 2024, Astrazeneca Pharma India Ltd is Undervalued by 37.98% compared to the current share price 6,305.00

Last 5 Year EPS CAGR: 14.05%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a low average Working Capital Days of -21.83, which is a positive sign.
  2. The company has higher reserves (353.54 cr) compared to borrowings (4.77 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (521.00 cr) and profit (57.15 cr) over the years.
  1. The stock has a low average ROCE of 10.75%, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 0.33, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Astrazeneca Pharma India Ltd:
    1. Net Profit Margin: 12.46%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 28.34% (Industry Average ROCE: 16.4%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 22.68% (Industry Average ROE: 16.92%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 121.83
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.97
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 122 (Industry average Stock P/E: 54.2)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

AstraZeneca Pharma India Ltd. is a Public Limited Listed company incorporated on 11/07/1979 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L24231KA1979PLC003563 and registration number is 003563. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 805.60 Cr. and Equity Capital is Rs. 5.00 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsBlock N1, 12th Floor, Bengaluru Karnataka 560045comp.secy@astrazeneca.com
http://www.astrazeneca.com/india
Management
NamePosition Held
Mr. Narayan K SeshadriChairperson & Independent Director
Mr. Sanjeev Kumar PanchalExecutive Director
Ms. Bhavana AgrawalExecutive Director
Ms. Sylvia Lorena Varela RamonNon Executive Director
Ms. Hooi Bien ChuahNon Executive Director
Ms. Shilpa Divekar NirulaIndependent Director
Ms. Revathy AshokIndependent Director

FAQ

What is the latest intrinsic value of Astrazeneca Pharma India Ltd?

The latest intrinsic value of Astrazeneca Pharma India Ltd as on 21 November 2024 is ₹7628.01, which is 20.98% higher than the current market price of ₹6,305.00.

What is the Market Cap of Astrazeneca Pharma India Ltd?

The Market Cap of Astrazeneca Pharma India Ltd is 15,762 Cr..

What is the current Stock Price of Astrazeneca Pharma India Ltd as on 21 November 2024?

The current stock price of Astrazeneca Pharma India Ltd as on 21 November 2024 is ₹6,305.

What is the High / Low of Astrazeneca Pharma India Ltd stocks in FY 2024?

In FY 2024, the High / Low of Astrazeneca Pharma India Ltd stocks is 8,140/4,050.

What is the Stock P/E of Astrazeneca Pharma India Ltd?

The Stock P/E of Astrazeneca Pharma India Ltd is 122.

What is the Book Value of Astrazeneca Pharma India Ltd?

The Book Value of Astrazeneca Pharma India Ltd is 272.

What is the Dividend Yield of Astrazeneca Pharma India Ltd?

The Dividend Yield of Astrazeneca Pharma India Ltd is 0.38 %.

What is the ROCE of Astrazeneca Pharma India Ltd?

The ROCE of Astrazeneca Pharma India Ltd is 31.1 %.

What is the ROE of Astrazeneca Pharma India Ltd?

The ROE of Astrazeneca Pharma India Ltd is 22.9 %.

What is the Face Value of Astrazeneca Pharma India Ltd?

The Face Value of Astrazeneca Pharma India Ltd is 2.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Astrazeneca Pharma India Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE